Tessier-Lavigne Marc
SEC-identified person · CIK 1437435 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Denali Therapeutics Inc. DNLI | Director | filed 2017–2025 |
| Regeneron Pharmaceuticals, INC. REGN | Director | filed 2011–2023 |
| Agios Pharmaceuticals, INC. AGIO | Director | filed 2013–2016 |
| Juno Therapeutics, Inc. JUNO | Director | filed 2014–2016 |
| Pfizer INC pfe | Director | filed 2011–2015 |
| Genentech INC DNA | EVP, RESEARCH DRUG DISCOVERY | filed 2008–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.